Rising Prevalence of Venous Diseases Are Anticipated to Grow The Venous Stents Market from 2018 to 2025.
The global venous stents market is expected to reach US$ 1,727.4 Mn in 2025 from US$ 829.0 in 2017. The market is estimated to grow with a CAGR of 9.7% from 2018-2025.
The prevalence of the venous disease are observed due to the conditions that include: venous thrombosis, deep vein thrombosis, venous stasis, venous ulcers, arteriovenous fistula, post-thrombotic syndrome, thrombophlebitis and others. According to the Johns Hopkins University around 15% of the US population suffers from varicose veins. Also, according to the Centers for Disease Control and Prevention, every year approximately 900,000 (1 – 2 per 1,000) people are affected by deep vein thrombosis (DVT) in the United States. It also mentioned that 33% of people with DVT will have recurrence of DVT within 10 years. Furthermore, thrombophilia is the condition wherein predisposition leads to formation of clots. The predisposition to form clots can arise from genetic factors, genetic thrombophilia results when there is deficiency in inherited factor, such as antithrombin or protein C. The Centers for Disease Control and Prevention estimated that 5-8% people in the US have inherited thrombophilias. Owing to the rising cases of venous diseases in the regions and in various countries, the need and demand for the venous stents for the treatment of the venous disorders increases, thus enhancing the venous stents market growth in the future years.
The growth of the venous stents market is also expected due to the increasing in the advancement in the technology for the stents and also the rising prevalence of the deep vein thrombosis in the elderly population are likely to drive the growth of the venous stents market. Whereas, developments for the advanced venous stents is the estimated to be the future trend for the growth of the venous stents market t. The demand for the venous is expected to increase in the forecast period due to the increasing prevalence of the deep vein thrombosis in the people having professions with long standing hours.
The major players manufacturing the venous stents market that are included in the report are Boston Scientific Corporation, C. R Bard (acquired by BD), Jotech GMBH (acquired by Cryolife, Inc.), Cook, W.L Gore & Associates, optimed Medizinische Instrumente GMBH, Medtronic, Medica Germany GMBH & Co. KG, and Cordis (acquired by Cardinal Health). The report also includes the recent developments done by the companies in the recent years. For instance, in 2016, W. L. Gore & Associates have received product approval from FDA for its self-expanding GORE TIGRIS Vascular Stent. In addition, in 2018, Boston Scientific Corporation has acquired Veniti Inc who has developed Vici Venous Stent System for treating venous obstructive disease.
